BPG is committed to discovery and dissemination of knowledge
About the Journal
Name of Journal World Journal of Gastrointestinal Oncology
Title Abbreviation World J Gastrointest Oncol
ISSN 1948-5204 (online)
DOI 10.4251
Background World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is a high-quality, online, open-access, single-blind peer-reviewed journal published by the Baishideng Publishing Group (Baishideng). WJGO accepts both solicited and unsolicited manuscripts. Articles published in WJGO are high-quality, clinical and basic, influential research articles by established academic authors as well as new researchers. The paramount objective of WJGO is to showcase and promote distinguished research in the field of gastrointestinal oncology, to help advance development of this field. The types of articles published in the WJGO include Editorial, Opinion Review, Frontier, Review, Minireview, Clinical Research, Basic Study, Systematic Review, Meta-analysis, Evidence-based Medicine, Field of Vision, Clinical Guidelines, Letter to the Editor, and Case Report.
Aim

The primary aim of WJGO is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality clinical and basic research articles and communicate their research findings online. In order to ensure the quality, timeliness, fairness, and transparency of publication, WJGO has implemented a variety of measures as follows: 

First, authors are recommended to prepare their articles according to the appropriate international publication recommendations, including the STROBE Statement, CONSORT 2010 Statement, PRISMA 2009 Checklist, and CARE Checklist – 2016: Information for writing a case report. It is recommended that non-native English-speaking authors improve the language quality of their manuscript before submitting. It is also recommended to all authors to perform automated similarity detection, such as with Similarity Check by CrossRef, to ensure the manuscript’s similarity is < 30%. Both of these two features are closely related to peer review and first-decision making for the manuscript. For all articles involving human studies and/or animal experiments, before their acceptance, author(s) must provide the related formal ethics documents that were reviewed and approved by their local ethical review committee. For full guidelines for authors, please visit: https://www.wjgnet.com/bpg/gerinfo/204.

Second, articles published in WJGO must undergo rigorous external, cross-international peer review. WJGO peer reviewers come from different countries, chosen independently by artificial intelligence technique or our Editorial Office, and not recommended by the authors, to ensure fairness and protect integrity of the peer review process. For the full peer-review process, please visit: https://www.wjgnet.com/bpg/gerinfo/241.

Third, designation of co-first authors and/or co-corresponding authors is permitted.  For the policy of allowing co-first authors and co-corresponding authors who made equal contribution to a manuscript, please visit: https://www.wjgnet.com/bpg/GerInfo/310.

Fourth, WJGO's acceptance of a manuscript for publication is based on its novelty, innovativeness, data accuracy, image reliability, clear language expression, and ethical requirements. 

Fifth, in general, for the majority of manuscripts submitted to any Baishideng journal, the first decision/peer review procedure can be done within 28 days from the date that the journal receives the manuscript, other than this the maximum time will not exceed 90 days; the second decision, from the author submission of the revised version to its final determination for acceptance/rejection can be done within 28 days, other than this the maximum time will not exceed 38 days; and most of the accepted papers can be published online within 20 days, other than this the maximum time will not exceed 30 days.

Finally, the peer review report, author’s response to the peer review report, biostatistics review certificate, copyright license agreement, institutional ethics committee approval document, informed consent document(s), conflict-of-interest statement, CrossCheck detection report, corresponding authors’ personal ORCID numbers, funding information, language editing certificate, and other relevant documents will be published online along with the article to allow for an open and transparent publishing process.

Scope WJGO mainly publishes articles reporting research results obtained in the field of gastrointestinal oncology and covering a wide range of topics, including islet cell adenoma, liver cell adenoma, adenomatous polyposis coli, appendiceal neoplasms, bile duct neoplasms, biliary tract neoplasms, hepatocellular carcinoma, islet cell carcinoma, pancreatic ductal carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, hereditary nonpolyposis colorectal neoplasms, common bile duct neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, Gardner syndrome, gastrinoma, gastrointestinal neoplasms, glucagonoma, ileal neoplasms, insulinoma, intestinal neoplasms, jejunal neoplasms, liver neoplasms, experimental liver neoplasms, pancreatic neoplasms, peritoneal neoplasms, rectal neoplasms, sigmoid neoplasms, somatostatinoma, stomach neoplasms, and vipoma.
Open Access Open access
Indexing/Abstracting The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database.
Journal Metrics The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJGO as 3.0; IF without journal self cites: 2.9; 5-year IF: 3.0; Journal Citation Indicator: 0.49; Ranking: 157 among 241 journals in oncology; Quartile category: Q3; Ranking: 58 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO’s CiteScore for 2022 is 4.1 and Scopus CiteScore rank 2022: Gastroenterology is 71/149; Oncology is 197/366.
Article Processing Charge Article processing charge
Editors-in-Chief Monjur Ahmed, Florin Burada
Publisher Publisher
Research Domain Gastroenterology and Hepatology
Article Reprints Article reprints
Permissions Permissions
Help Desk Help desk
Special Statement Special statement
Copyright © © 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Contact Us Contact us